

Mark Sculpher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8974911/publications.pdf>

Version: 2024-02-01

145
papers

10,343
citations

47006

47
h-index

34986

98
g-index

148
all docs

148
docs citations

148
times ranked

12362
citing authors

#	ARTICLE	IF	CITATIONS
1	Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics (United Kingdom), 2001, 10, 779-787.	1.7	885
2	An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics, 1998, 13, 397-409.	3.3	713
3	Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value in Health, 2016, 19, 929-935.	0.3	589
4	Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technology Assessment, 2015, 19, 1-504.	2.8	536
5	Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Economics (United Kingdom), 1994, 3, 95-104.	1.7	487
6	Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet, The, 2017, 390, 1048-1060.	13.7	448
7	Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report. Value in Health, 2009, 12, 409-418.	0.3	395
8	A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet, The, 2002, 360, 711-715.	13.7	378
9	Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics (United Kingdom), 2005, 14, 339-347.	1.7	368
10	Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations. Health Policy, 2009, 93, 85-92.	3.0	227
11	Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates. JAMA - Journal of the American Medical Association, 2016, 316, 1051.	7.4	227
12	Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies. International Journal of Technology Assessment in Health Care, 2005, 21, 165-171.	0.5	202
13	Assessing Quality in Decision Analytic Cost-Effectiveness Models. Pharmacoeconomics, 2000, 17, 461-477.	3.3	172
14	The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment. Journal of Health Services Research and Policy, 1997, 2, 26-30.	1.7	161
15	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy, 2007, 12, 56-58.	1.7	155
16	Should Patients Have a Greater Role in Valuing Health States?. Applied Health Economics and Health Policy, 2005, 4, 201-208.	2.1	139
17	Cost effectiveness analysis of laparoscopic hysterectomy compared with standard hysterectomy: results from a randomised trial. BMJ: British Medical Journal, 2004, 328, 134-0.	2.3	138
18	Subgroups and Heterogeneity in Cost-Effectiveness Analysis. Pharmacoeconomics, 2008, 26, 799-806.	3.3	129

#	ARTICLE	IF	CITATIONS
19	The Value of Implementation and the Value of Information: Combined and Uneven Development. <i>Medical Decision Making</i> , 2008, 28, 21-32.	2.4	127
20	Characterizing Structural Uncertainty in Decision Analytic Models: A Review and Application of Methods. <i>Value in Health</i> , 2009, 12, 739-749.	0.3	123
21	Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. <i>BMJ: British Medical Journal</i> , 2004, 328, 382.	2.3	120
22	Acupuncture and Counselling for Depression in Primary Care: A Randomised Controlled Trial. <i>PLoS Medicine</i> , 2013, 10, e1001518.	8.4	106
23	Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions. <i>Value in Health</i> , 2012, 15, 570-579.	0.3	101
24	Sensitivity analysis in economic evaluation: A review of published studies. <i>Health Economics (United Kingdom)</i> , 2006, 15, 1-4.	1.7	99
25	Quality-adjusted life years. <i>Practical Neurology</i> , 2008, 8, 175-182.	1.1	98
26	Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. <i>International Journal of Technology Assessment in Health Care</i> , 2005, 21, 165-71.	0.5	96
27	Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence?. <i>Value in Health</i> , 2005, 8, 433-446.	0.3	93
28	Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study. <i>Heart</i> , 2013, 99, 873-881.	2.9	90
29	CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?. <i>Health Economics (United Kingdom)</i> , 2015, 24, 1-7.	1.7	88
30	Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. <i>Health Economics (United Kingdom)</i> , 2006, 15, 1-4.	1.7	79
31	What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?. <i>Value in Health</i> , 2010, 13, 1028-1037.	0.3	77
32	Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 577-590.	2.1	73
33	Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. <i>Health Economics (United Kingdom)</i> , 2006, 15, 373-381.	1.7	71
34	The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-348.	2.8	71
35	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. <i>Health Technology Assessment</i> , 2018, 22, 1-176.	2.8	70
36	The Use of MCDA in HTA: Great Potential, but More Effort Needed. <i>Value in Health</i> , 2018, 21, 394-397.	0.3	67

#	ARTICLE	IF	CITATIONS
37	Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis. <i>Intensive Care Medicine</i> , 2002, 28, 599-608.	8.2	64
38	Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions. <i>Value in Health</i> , 2017, 20, 234-239.	0.3	64
39	Value for money and the Quality and Outcomes Framework in primary care in the UK NHS. <i>British Journal of General Practice</i> , 2010, 60, e213-e220.	1.4	61
40	Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial. <i>JACC: Heart Failure</i> , 2018, 6, 517-526.	4.1	59
41	Recognizing diversity in public preferences: The use of preference sub-groups in cost-effectiveness analysis. <i>Health Economics (United Kingdom)</i> , 2001, 10, 317-324.	1.7	56
42	Efficiency, Equity, and Budgetary Policies. <i>Medical Decision Making</i> , 2007, 27, 128-137.	2.4	56
43	Cost-Effectiveness Analysis of Stratified Versus Stepped Care Strategies for Acute Treatment of Migraine. <i>Pharmacoeconomics</i> , 2002, 20, 91-100.	3.3	52
44	Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. <i>Health Economics (United Kingdom)</i> , 2017, 26, 109-123.	1.7	52
45	Estimating utility data from clinical indicators for patients with stable angina. <i>European Journal of Health Economics</i> , 2005, 6, 347-353.	2.8	51
46	Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. <i>PLoS ONE</i> , 2017, 12, e0172749.	2.5	51
47	Probabilistic Analysis and Computationally Expensive Models: Necessary and Required?. <i>Value in Health</i> , 2006, 9, 244-252.	0.3	49
48	The EOS 2D/3D X-ray imaging system: A cost-effectiveness analysis quantifying the health benefits from reduced radiation exposure. <i>European Journal of Radiology</i> , 2013, 82, e342-e349.	2.6	49
49	Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 2, 125-140.	4.0	49
50	Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk. <i>BMJ Open</i> , 2020, 10, e037075.	1.9	48
51	Results of the Economic Evaluation of the FIRST Study: A Multinational Prospective Economic Evaluation. <i>International Journal of Technology Assessment in Health Care</i> , 1996, 12, 698-713.	0.5	47
52	An Iterative Bayesian Approach to Health Technology Assessment: Application to a Policy of Preoperative Optimization for Patients Undergoing Major Elective Surgery. <i>Medical Decision Making</i> , 2006, 26, 480-496.	2.4	47
53	Eliciting Distributions to Populate Decision Analytic Models. <i>Value in Health</i> , 2010, 13, 557-564.	0.3	47
54	The Use of Probabilistic Decision Models in Technology Assessment. <i>Applied Health Economics and Health Policy</i> , 2004, 3, 79-89.	2.1	45

#	ARTICLE	IF	CITATIONS
55	A Cost-Utility Analysis of Abdominal Hysterectomy Versus Transcervical Endometrial Resection for the Surgical Treatment of Menorrhagia. <i>International Journal of Technology Assessment in Health Care</i> , 1998, 14, 302-319.	0.5	42
56	Supporting the development of a health benefits package in Malawi. <i>BMJ Global Health</i> , 2018, 3, e000607.	4.7	42
57	Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIa antagonists in the UK National Health Service?. <i>International Journal of Cardiology</i> , 2005, 100, 229-240.	1.7	39
58	Early infant diagnosis of HIV infection in low-income and middle-income countries: does one size fit all?. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 650-655.	9.1	38
59	Cost-effectiveness of integrated collaborative care for comorbid major depression in patients with cancer. <i>Journal of Psychosomatic Research</i> , 2015, 79, 465-470.	2.6	37
60	A Cost-Utility Analysis of Laser-Assisted Angioplasty for Peripheral Arterial Occlusions. <i>International Journal of Technology Assessment in Health Care</i> , 1996, 12, 104-125.	0.5	34
61	Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions. <i>Social Science and Medicine</i> , 2002, 54, 1369-1377.	3.8	34
62	Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling. <i>Medical Decision Making</i> , 2007, 27, 471-490.	2.4	33
63	Cost-utility of transcatheter aortic valve implantation for inoperable patients with severe aortic stenosis treated by medical management: a UK cost-utility analysis based on patient-level data from the ADVANCE study. <i>Open Heart</i> , 2014, 1, e000155.	2.3	33
64	Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response. <i>Medical Decision Making</i> , 2005, 25, 511-519.	2.4	32
65	Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. <i>Heart</i> , 2016, 102, 1742-1749.	2.9	30
66	The Economic Evaluation of the FIRST Study: Design of a prospective analysis alongside a multinational phase III clinical trial. <i>Contemporary Clinical Trials</i> , 1996, 17, 304-315.	1.9	29
67	Who Does the Numbers? The Role of Third-Party Technology Assessment to Inform Health Systems' Decision-Making about the Funding of Health Technologies. <i>Value in Health</i> , 2009, 12, 193-201.	0.3	29
68	Sins of omission and obfuscation: IQWiG's guidelines on economic evaluation methods. <i>Health Economics (United Kingdom)</i> , 2010, 19, 1132-1136.	1.7	28
69	Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e418-e442.	1.9	28
70	Adherence to the iDSI reference case among published cost-per-DALY averted studies. <i>PLoS ONE</i> , 2019, 14, e0205633.	2.5	27
71	Acupuncture for chronic pain and depression in primary care: a programme of research. <i>Programme Grants for Applied Research</i> , 2017, 5, 1-316.	1.0	27
72	The cost-effectiveness of preference-based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia. , 1998, 7, 129-142.		26

#	ARTICLE	IF	CITATIONS
73	Cancer Drugs Fund requires further reform. <i>BMJ, The</i> , 2016, 354, i5090.	6.0	26
74	Using electronic health records to predict costs and outcomes in stable coronary artery disease. <i>Heart</i> , 2016, 102, 755-762.	2.9	26
75	Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial. <i>Advances in Therapy</i> , 2017, 34, 753-764.	2.9	26
76	Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model. <i>Medical Decision Making</i> , 2005, 25, 493-510.	2.4	25
77	Economic Evaluation of Coronary Artery Bypass Grafting Surgery With and Without Cardiopulmonary Bypass: Cost-Effectiveness and Quality-Adjusted Life Years in a Randomized Controlled Trial. <i>Artificial Organs</i> , 2008, 32, 891-897.	1.9	25
78	Glycopeptide vs. Non-Glycopeptide Antibiotics for Prophylaxis of Surgical Site Infections: A Systematic Review. <i>Surgical Infections</i> , 2010, 11, 455-462.	1.4	25
79	Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE-MARC 2): A prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease. <i>American Heart Journal</i> , 2015, 169, 17-24.e1.	2.7	25
80	Is self-care a cost-effective use of resources? Evidence from a randomized trial in inflammatory bowel disease. <i>Journal of Health Services Research and Policy</i> , 2006, 11, 225-230.	1.7	24
81	Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?. <i>Value in Health</i> , 2016, 19, 138-144.	0.3	24
82	Patient Characteristics Impacting Health State Index Scores, Measured by the EQ-5D of Females with Stress Urinary Incontinence Symptoms. <i>Value in Health</i> , 2010, 13, 112-118.	0.3	22
83	Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. <i>Value in Health</i> , 2021, 24, 1828-1834.	0.3	22
84	The Costs and Benefits of Primary Total Hip Replacement: How Likely Are New Prostheses To Be Cost-effective?. <i>International Journal of Technology Assessment in Health Care</i> , 1998, 14, 743-761.	0.5	20
85	The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial. <i>Value in Health</i> , 2016, 19, 431-439.	0.3	20
86	Cost-Effectiveness of diagnosis as a metric for monitoring cost-effectiveness of HIV testing programmes in low-income settings in southern Africa: health economic and modelling analysis. <i>Journal of the International AIDS Society</i> , 2019, 22, e25325.	3.0	20
87	How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants. <i>Medical Decision Making</i> , 2017, 37, 148-161.	2.4	18
88	Economic analysis of service and delivery interventions in health care. <i>Health Services and Delivery Research</i> , 2018, 6, 1-16.	1.4	18
89	A cost effectiveness analysis of goserelin compared with danazol as endometrial thinning agents. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 340-346.	2.3	17
90	NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium. <i>BMJ Open</i> , 2012, 2, e000671.	1.9	17

#	ARTICLE	IF	CITATIONS
91	Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. <i>Journal of Medical Economics</i> , 2013, 16, 510-521.	2.1	15
92	Modelling the Health and Economic Impacts of Population-Wide Testing, Contact Tracing and Isolation (PTTI) Strategies for COVID-19 in the UK. <i>SSRN Electronic Journal</i> , 0, , .	0.4	15
93	Cost-Effectiveness of Duloxetine: The Stress Urinary Incontinence Treatment (SUIT) Study. <i>Value in Health</i> , 2010, 13, 565-572.	0.3	14
94	Developing the EQ-5D-5L Value Set for Uganda Using the "Lite"™ Protocol. <i>Pharmacoeconomics</i> , 2022, 40, 309-321.	3.3	14
95	Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010471.	3.0	14
96	Real Economics Needs to Reflect Real Decisions. <i>Pharmacoeconomics</i> , 2012, 30, 133-136.	3.3	13
97	Clinical Trials Provide Essential Evidence, but Rarely Offer a Vehicle for Cost-Effectiveness Analysis. <i>Value in Health</i> , 2015, 18, 141-142.	0.3	13
98	Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , 2016, 214, 73-79.	4.0	13
99	The HOME Study: study protocol for a randomised controlled trial comparing the addition of Proactive Psychological Medicine to usual care, with usual care alone, on the time spent in hospital by older acute hospital inpatients. <i>Trials</i> , 2019, 20, 483.	1.6	13
100	After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?. <i>Pharmacoeconomics</i> , 2020, 38, 247-257.	3.3	13
101	Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial. <i>PLoS ONE</i> , 2014, 9, e113726.	2.5	13
102	Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV. <i>Medical Decision Making</i> , 2012, 32, 70-82.	2.4	12
103	Cost-effectiveness of cardiovascular imaging for stable coronary heart disease. <i>Heart</i> , 2021, 107, 381-388.	2.9	12
104	Reflecting Heterogeneity in Patient Benefits: The Role of Subgroup Analysis with Comparative Effectiveness. <i>Value in Health</i> , 2010, 13, S18-S21.	0.3	11
105	Methods for network meta-analysis of continuous outcomes using individual patient data: a case study in acupuncture for chronic pain. <i>BMC Medical Research Methodology</i> , 2016, 16, 131.	3.1	11
106	Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research. <i>Genetic Testing and Molecular Biomarkers</i> , 2017, 21, 705-716.	0.7	11
107	The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. <i>Health Technology Assessment</i> , 2016, 20, 1-158.	2.8	11
108	Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial. <i>European Journal of Haematology</i> , 2014, 92, 249-255.	2.2	10

#	ARTICLE	IF	CITATIONS
109	The economics of medicines optimization: policy developments, remaining challenges and research priorities. <i>British Medical Bulletin</i> , 2014, 111, 45-61.	6.9	10
110	Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial. <i>Pharmacoeconomics</i> , 2016, 34, 795-804.	3.3	9
111	Ideas About Resourcing Health Care in the United States: Can Economic Evaluation Achieve Meaningful Use?. <i>Annals of Internal Medicine</i> , 2021, 174, 80-85.	3.9	9
112	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>European Journal of Health Economics</i> , 2022, 23, 1309-1317.	2.8	9
113	Using Economic Evaluations to Reduce the Burden of Asthma and Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2001, 19, 21-25.	3.3	8
114	Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Authors' reply. <i>Health Economics (United Kingdom)</i> , 2002, 11, 653-654.	1.7	8
115	Cost-effectiveness of enhanced external counterpulsation (EECP) for the treatment of stable angina in the United Kingdom. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 175-182.	0.5	8
116	Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV. <i>MDM Policy and Practice</i> , 2017, 2, 238146831771644.	0.9	8
117	Real-world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non-valvular atrial fibrillation patients in England. <i>Journal of Evaluation in Clinical Practice</i> , 2021, 27, 119-133.	1.8	8
118	Program Evaluation of Population- and System-Level Policies: Evidence for Decision Making. <i>Medical Decision Making</i> , 2022, 42, 17-27.	2.4	8
119	Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2649-2666.	1.7	8
120	The Cost Implications of an Asthma Attack. <i>Pediatric Asthma, Allergy and Immunology</i> , 1998, 12, 193-198.	0.2	7
121	Reforming the Cancer Drug Fund. <i>BMJ, The</i> , 2014, 349, g7276-g7276.	6.0	7
122	Distributional cost effectiveness analysis of West Yorkshire low emission zone policies. <i>Health Economics (United Kingdom)</i> , 2020, 29, 567-579.	1.7	7
123	Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19498.	3.0	6
124	Should the Lambda (λ) Remain Silent?. <i>Pharmacoeconomics</i> , 2016, 34, 323-329.	3.3	6
125	ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics. <i>Value in Health</i> , 2018, 21, 171-172.	0.3	6
126	Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies. <i>Pharmacoeconomics</i> , 2021, 39, 879-887.	3.3	6

#	ARTICLE	IF	CITATIONS
127	Making decisions under uncertainty—the role of probabilistic decision modelling. <i>Family Practice</i> , 2006, 23, 391-392.	1.9	5
128	Effect of management strategies and clinical status on costs of care for advanced HIV. <i>American Journal of Managed Care</i> , 2014, 20, e129-37.	1.1	5
129	Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research. <i>Substance Use and Misuse</i> , 2022, 57, 815-821.	1.4	5
130	Benefit Valuation in Economic Evaluation of Cancer Therapies. <i>Pharmacoeconomics</i> , 1999, 16, 17-31.	3.3	4
131	Understanding Harris's™ understanding of CEA: Is cost effective resource allocation undone?. <i>Journal of Health Services Research and Policy</i> , 2013, 18, 34-39.	1.7	4
132	Cost of coronary angioplasty versus coronary artery bypass surgery. <i>Lancet</i> , The, 1994, 344, 1574-1575.	13.7	3
133	Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 15.	1.5	3
134	The HOME Study: Statistical and economic analysis plan for a randomised controlled trial comparing the addition of Proactive Psychological Medicine to usual care, with usual care alone, on the time spent in hospital by older acute hospital inpatients. <i>Trials</i> , 2020, 21, 373.	1.6	3
135	From impact evaluation to decision-analysis: assessing the extent and quality of evidence on "value for money"™ in health impact evaluations in low- and middle-income countries. <i>Gates Open Research</i> , 0, 5, 1.	1.1	3
136	Searching for a threshold "Not so". <i>Journal of Health Services Research and Policy</i> , 2007, 12, 190-191.	1.7	2
137	Impact of missed treatment opportunities on outcomes in hospitalised patients with heart failure. <i>Open Heart</i> , 2017, 4, e000726.	2.3	2
138	Social value and individual choice: The value of a choice-based decision-making process in a collectively funded health system. <i>Health Economics (United Kingdom)</i> , 2018, 27, e28-e40.	1.7	2
139	Methodological issues in economic evaluations of emergency transport systems in low-income and middle-income countries. <i>BMJ Global Health</i> , 2021, 6, e004723.	4.7	2
140	9 Economic evaluation in obstetrics and gynaecology. <i>Bailliere's Clinical Obstetrics and Gynaecology</i> , 1996, 10, 661-675.	0.6	0
141	Linee guida di buona pratica per creare modelli analitico-decisionali nella valutazione delle tecnologie sanitarie. <i>Giornale Italiano Di Health Technology Assessment</i> , 2008, 1, 1-14.	0.1	0
142	Valutazione di tecnologia singola presso l'Istituto Nazionale per l'Eccellenza Sanitaria e Clinica del Regno Unito. <i>Pharmacoeconomics Italian Research Articles</i> , 2011, 13, 5-8.	0.2	0
143	Alitretinoina nell'eczema cronico grave alle mani. Valutazione di tecnologia singola presso il NICE. <i>Pharmacoeconomics Italian Research Articles</i> , 2011, 13, 9-20.	0.2	0
144	Methods Development for Health Technology Assessment. <i>Medical Decision Making</i> , 2013, 33, 313-315.	2.4	0

#	ARTICLE	IF	CITATIONS
145	Quantifying patient centered outcomes associated with the use of bilateral endobronchial coil treatment in patients with severe emphysema. Current Medical Research and Opinion, 2018, 34, 1927-1932.	1.9	0